• Dose-limiting toxicity and treatment-emergent adverse events • Confirmed best overall response (BOR) • Immune-related best overall response (irBOR) and best overall response (BOR)• Overall survival time (OS) and progression-free survival (PFS) time • Level of PD-L1 tumor expression, etc. The gene discussed is CD274; the disease is neoplasm.